Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash from Operations (2020 - 2026)

Cytek Biosciences filings provide 6 years of Cash from Operations readings, the most recent being 771000.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 138.61% to 771000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 4686000.0, a 118.46% decrease, with the full-year FY2025 number at 4686000.0, down 118.46% from a year prior.
  • Cash from Operations hit 771000.0 in Q4 2025 for Cytek Biosciences, up from 3898000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13221000.0 in Q3 2024 to a low of 9440000.0 in Q2 2022.
  • Median Cash from Operations over the past 5 years was 634500.0 (2021), compared with a mean of 918650.0.
  • Biggest five-year swings in Cash from Operations: tumbled 746.34% in 2022 and later surged 411.89% in 2024.
  • Cytek Biosciences' Cash from Operations stood at 5448000.0 in 2021, then grew by 13.67% to 6193000.0 in 2022, then surged by 53.59% to 9512000.0 in 2023, then plummeted by 79.01% to 1997000.0 in 2024, then tumbled by 138.61% to 771000.0 in 2025.
  • The last three reported values for Cash from Operations were 771000.0 (Q4 2025), 3898000.0 (Q3 2025), and 108000.0 (Q2 2025) per Business Quant data.